Literature DB >> 18307625

The electrical substrate of vagal atrial fibrillation as assessed by the signal-averaged electrocardiogram of the P wave.

Dmitry Nemirovsky1, Randolph Hutter, J Anthony Gomes.   

Abstract

BACKGROUND: The autonomic nervous system is thought to be involved in the initiation of atrial fibrillation (AF). However, there is a distinct entity of vagal AF characterized by episodes occurring at rest, postprandially, or during sleep. The purpose of this study was to compare intraatrial conduction in patients with vagally mediated AF to those with nonvagal AF, using the signal-averaged electrocardiogram (SAECG) of P wave.
METHODS: SAECG of P wave was performed in 58 patients with AF using the Marquette Medical System, and the mean filtered P-wave duration (SAPW) was measured. Nine patients were categorized as having pure vagal AF (Group I), and 42 patients as having nonvagal AF (Group II); the remaining seven patients were excluded from analysis because of incomplete data.
RESULTS: The patients in Group I were significantly younger and more likely to have paroxysmal lone AF, as compared to those in Group II. There was no significant difference in left atrial size and left ventricular function in the two groups. The mean SAPW was significantly shorter in Group I when compared to Group II (118 +/- 5 ms vs 149 +/- 39 ms, P < 0.001). Whereas all patients in Group I had a normal SAPW, 79% of patients in Group II had an abnormal SAPW (P < 0.001). A normal SAPW was significantly predictive of vagal AF independent of other co-variables.
CONCLUSIONS: (1) Patients with vagal AF are younger, and invariably have paroxysmal lone AF. (2) SAPW is normal and significantly shorter in vagal AF when compared to patients with nonvagal AF. (3) This suggests that those in the vagal AF population have normal intraatrial conduction, which has implications for AF ablation in these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18307625     DOI: 10.1111/j.1540-8159.2008.00990.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

Review 1.  P-wave morphology: underlying mechanisms and clinical implications.

Authors:  Pyotr G Platonov
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-07       Impact factor: 1.468

Review 2.  Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system.

Authors:  Rishi Arora
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-08-01

3.  Alcohol and vagal tone as triggers for paroxysmal atrial fibrillation.

Authors:  Mala C Mandyam; Vasanth Vedantham; Melvin M Scheinman; Zian H Tseng; Nitish Badhwar; Byron K Lee; Randall J Lee; Edward P Gerstenfeld; Jeffrey E Olgin; Gregory M Marcus
Journal:  Am J Cardiol       Date:  2012-04-20       Impact factor: 2.778

4.  Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature.

Authors:  Pattara Rattanawong; Jakrin Kewcharoen; Komandoor S Srivathsan; Win-Kuang Shen
Journal:  J Atr Fibrillation       Date:  2020-06-30

5.  Association between heart rate and cardiovascular death in patients with coronary heart disease: A NHANES-based cohort study.

Authors:  Ruicong Ma; Jianbo Gao; Shiyuan Mao; Zhirong Wang
Journal:  Clin Cardiol       Date:  2022-03-30       Impact factor: 3.287

6.  P-wave duration in lead aVR and the risk of atrial fibrillation in hypertension.

Authors:  Pietro Francia; Agnese Ricotta; Cristina Balla; Carmen Adduci; Lorenzo Semprini; Alessandra Frattari; Anna Modestino; Federico Mercanti; Isabella Sensini; Massimo Caprinozzi; Giuliano Tocci; Massimo Volpe
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-09-09       Impact factor: 1.468

Review 7.  Heart rate reduction in coronary artery disease and heart failure.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Nat Rev Cardiol       Date:  2016-05-26       Impact factor: 32.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.